Riskpilot← Back to searchSign inGet full accessDsruptive Subdermals AB
ABActiveOrg 5591898852Hammarvägen 2 Lgh 1102Engineering activities and related technical consultancy · NACE 7112Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
-214% vs 2023
Equity ratio
99.5%
Financial strength
Net profit 2024
SEK -168K
-136% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -160K | -214% |
| Net profit | SEK -168K | -136% |
| Total assets | SEK 1,4M | -16% |
| Equity | SEK 1,4M | -11% |
| Employees | 0 | — |
Legal name
Dsruptive Subdermals AB
Org number
5591898852
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
7 januari 2019
Share capital
SEK 71 576
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva verksamhet inom industridesign, varumärkesutveckling, affärsutveckling, verksamhetsutveckling och därmed förenlig verksamhet.
Address
Hammarvägen 2 Lgh 1102
Email
info@nordicclinic.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 103 | 141 | 288 | 0 | 0 |
| Staff expenses | — | — | −0 | — | — |
| EBITDA | −146 | −1 048 | −205 | −51 | −160 |
| Depreciation & amort. | −1 | −5 | −154 | −5 | −5 |
| EBIT | −147 | −1 053 | −359 | −56 | −165 |
| Net financials | −17 | −13 | −16 | −15 | −3 |
| Profit before tax | −164 | −1 066 | −375 | −71 | −168 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −164 | −1 066 | −375 | −71 | −168 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 477 | 2 221 | 1 807 | 1 687 | 1 422 |
| Equity | 963 | 1 927 | 1 655 | 1 583 | 1 415 |
| Long-term debt | 500 | 196 | 146 | 96 | 0 |
| Short-term debt | 14 | 98 | 6 | 8 | 7 |
| Total debt | 514 | 294 | 152 | 103 | 7 |
EBITDA margin
-16038000.0%
This company
15.8%
Market median
-101506429% vs market
20202024
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20202024
Return on equity
-11.9%
This company
18.4%
Market median
-165% vs market
20202024
Net profit margin
-16816200.0%
This company
8.1%
Market median
-207607507% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
GH Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (1) | ||
| Chairman | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Dsruptive Subdermals AB (this company)
DSRUPTIVE SLDsruptive SlBoard members of Dsruptive Subdermals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gustav Hannes Hani Sjöblad | Chief Executive Officer | 0 companies |
| Anne Catherine Færgemann Moore | Deputy Board Member | 0 companies |
| Juan Jose Tara Ortiz | Board of Directors | 0 companies |
| Patric Lanhed | Chairman | 0 companies |
| Christopher Johan Liebe Moore | Chairman | 0 companies |